Amphastar Pharmaceuticals

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets a diverse portfolio of generic and proprietary products. The company was co-founded in 1996 by Dr. Jack Yongfeng Zhang and Dr. Mary Ziping Luo. Dr. Zhang, who serves as CEO, President, and Chief Scientific Officer, holds a Ph.D. in Chemistry from the State University of New York at Stony Brook and was a post-doctoral research associate at the California Institute of Technology. Dr. Luo, the Chief Operations Officer and Chairwoman of the Board, earned her Ph.D. in Chemistry from Princeton University and also conducted post-doctoral research at Caltech. Her journey is particularly notable, having overcome significant adversity during China's Cultural Revolution to become the only woman and the youngest of a small cohort to pass the exams for graduate study abroad in 1980.

The company focuses on technically challenging injectable, inhalation, and intranasal products, which often have high barriers to entry. This strategy allows Amphastar to operate in niche markets with less competition. Its business model is centered on a vertically integrated production process, which helps control quality and costs. Revenue is generated primarily through the sale of its pharmaceutical products to hospitals, long-term care facilities, clinics, and retail pharmacies. Distribution is handled through specialty distributors, wholesalers, and group purchasing organizations, primarily in the United States, but also in France and China. As of 2023, branded pharmaceuticals constituted 35% of the product lineup, with generics making up the remaining 65%. A key element of Amphastar's strategy involves a shift towards proprietary and biosimilar products, aiming to significantly increase their share of the development pipeline by 2026.

Amphastar's product portfolio includes well-known names such as the over-the-counter Primatene MIST inhalation aerosol and BAQSIMI, a nasal powder for severe hypoglycemia acquired from Eli Lilly in 2023. Other significant products include enoxaparin sodium injection, glucagon, naloxone, and lidocaine. The company also produces and sells insulin active pharmaceutical ingredients (APIs). Amphastar maintains a robust development pipeline, targeting markets with a combined size of over $10 billion. This includes several Abbreviated New Drug Applications (ANDAs) and biosimilar candidates for insulin and other treatments. A significant corporate milestone was the 2023 acquisition of BAQSIMI for over $1 billion, substantially strengthening its specialty product offering. The company is also making substantial investments in its infrastructure, with plans to quadruple its domestic manufacturing capacity at its Rancho Cucamonga, California headquarters.